Jefferies Global Healthcare Conference in London - AN2 THERAPEUTICS INC
Hi, everyone. Good morning. Welcome to the 2026 Jeffries Health Care Conference. It's my pleasure to welcome Eric Esom, CEO of Antu Therapeutics. Thank you. All right. Thank you very much. I'll be making certain forward-looking statements, so I wanted to make sure that that was known. So, okay, to introduce AN2 Therapeutics. So we are a boron chemistry platform-based company, and we have a strong clinical pipeline with three clinical proof of concept studies that are either ongoing or very close to starting in the next few weeks. We've got three of those. Our lead program is in hematology for polycythemia I'll talk a lot more about that in this session. We also have two other projects for NTM, non-tuberculous mycobacterial lung disease, targeting mycobiacterium abscessus as well as Chagas disease. So these are all proof of concept. They're novel. Two of these indications have no FDA approved drugs. So we're very excited about the potential of these to help patients. So near term catalyst. We've got a very catalyst-rich 2027, and we've got all three of these will be reading out. Nearest term will be the polycythemia vera trial, and that we'll see starting as soon as the first quarter and throughout 2027. We also have a robust research R&D pipeline that has a couple of development compounds that we've recently announced in oncology for ENPP-1, And then most recently for hypophosphatation, oral ENPP1 inhibitor, they were also excited. So we've got a lot going on and a very productive boron platform here. Okay, just to look at it in kind of a traditional pipeline sense. So this shows the three lead compounds. But the main point I wanted to make here is that, you know, we're a platform company and we, you know, follow biology. So we've really expanded our focus from originally we were more focused on infectious diseases. Now we have a very robust hematology and oncology pipeline with a very unique chemistry approach to it. We've got, you know, a strong infectious diseases pipeline with products that address high unmet needs and also have high commercial potential. And then recently, as I mentioned, we have a rare bone disorder project in hypophosphatasia that we're very excited about. And then something that's near and dear to us as a company that kind of sets us uniquely apart is we've been involved in global health from our earlier Anacor days up to A&2. And so we have an number of projects there. We've discovered probably 15 compounds for infectious diseases for those who don't know us, including tuberculosis, malaria, lots of major global health problems. So we're very supportive of doing that with non-diluted funding from Gates Foundation and governments and so forth. Okay, so I think the real interest is near term, is inflection points and value creation in terms of Phase II readouts. So as I mentioned, we have three proof-of-concept readouts, all three of these I think are significant value inflection points for for us as a company and really to prove out these compounds so we have multiple shots on goal if you will pv being the first of those so polycythemia vera we have phase two we're going to initiate the phase two and have first patient dose this year so this this study is starting imminently we'll have the first kind of safety read of the data in in the first quarter And then throughout 2027, we'll have efficacy data. That's an open lab trial, and I'll talk a lot more in detail about that. But this is a once-daily oral red cell targeted therapy for PV, which is a highly sought profile compared to a lot of injectables and off-target. Chagas disease, too, and i'll talk more about this, but we have a potential oral cure for this disease. Currently, the therapy available is not great. And so we really are excited about that. The disease affects 10 million people, 300,000 of which or more live in the United States. So this is kind of an unknown disease to many people, but 10 million people have parasites in their heart. It's a silent killer, and it's a major health, unaddressed health issue. NTM is Mycobacterium Abscessus. You know, this is one where there's, again, like Chagas, there's no FDA-approved drugs for mycobacterium abscesses. There's 15,000 patients in the U.S., and I'll talk more about that. So we'll have data on all three of those in 2027. So it's a, you know, lots of data inflection points coming in our near future. And then our earlier pipeline, we have three exciting programs, and these will be making further development into clinical trials in late 2027 and forward. So a lot more to come on those. All right. So we want to spend a lot of time on polycythemia vera. So this is a, you know, it's a, our compound is a petri-boral. It's in phase two, starting imminently. As I mentioned, it is oral and it is red cell targeting. So the real profile, I think, that is highly sought is a once a day oral therapy. We have vast amounts of clinical and preclinical data in non-PV patients showing the profile of red cell targeting, hematocrit reduction, which is exactly what you want with this, and selectivity without having lots of off-target activity around that. So we'll have data throughout 2027, and this is really the top priority, I think, in the near term for us as a company. so polycythemia vera you know this is a disease where there's an overproduction of red blood cells which leads to kind of a thickening or higher viscosity in your blood and a high risk of thrombotic events for patients with this so the primary uh treatment for this you want to keep hematocrit below 45 percent and keep it in normal these patients have super high hematocrits so they have more red blood cells and less room for the cells to flow throughout the body. So currently, the primary treatment is phlebotomies. So for a lifetime, you have to get a phlepotomy. You know, in many patients, it's, you know, every other month, every month. You can imagine using therapeutic, you know, bloodletting essentially as your therapy. And low-dose aspirin to manage platelets. And so there also are cytoreductive agents, but these have lots of off-target activities. They're injectables, other non-desirable features. So the idea is to have a red cell targeting oral therapy that doesn't have a lot of side effects and that's what we believe we have the potential for and we're going to be testing. Okay so I mentioned lots of clinical data. I just highlight one here. So this was from a compound that we this is a petra boral we studied in a phase two three non tuberculous mycobacteria lung disease trial and as you can see our drug on top of a optimized background regimen of multi antibiotics had a clear effect on hematocrit lowering so it's almost like the perfect step function if you will it goes down over the first four to eight weeks then it plateaus and there's a compensatory action going and it maintains that and then as soon as you take drug off it returns to baseline so this is very reproducible across you know we've run more than 10 clinical trials and see the same phenotype red cell targeting agent we also see you know a very well tolerated profile and we've seen it in preclinical we've done lots of NHP studies to also show this and look at PKPD, et cetera. So we've got lots of non-PV data. So the real question for us is, will this translate to patients with polycythemia vera, which we think it will. This just shows kind of the off-target effect. So essentially, it has absolutely no effect on white blood cells and platelets. They stay within normal range and very, very minor deviation. So this is unique in the fact that it's oral and doesn't have that makes it very red cell specific, which is the exciting part of the profile. All right, so in terms of clinical trial, I mentioned we're going to be starting our trial in PV this year. So we'll be dosing the first patient sometime in the coming weeks with a Sentinel cohort. So there's going to Be initial 10 patients at a very low dose in a Sentinel just because we've never dosed a PV patient to see if we see all the right safety features and kind of phenotype, but it's mainly a safety readout, and that will happen in the first quarter. So that's the planned timeline for when we'll read out that, and then they'll go straight into this part one, which is all this is open label, so we'll be able to see these data in real time. And the dose titration will start with a fairly low dose and then allow on a per-patient basis for the dose to be escalated over a long enough period that we can really show the primary purpose of this, which is to reduce the need for therapeutic phlebotomies. So that's really exciting. We'll start having patients hit the 20-week mark sometime around mid-year, and we'll do data cuts. So we're not going to wait until we have all 75 to release data. We'll have early readouts and then throughout 2027 on that. And then there's a part two, which will then randomize patients off of therapy. And we think you will see them go back out of control with phlebotomy only and then those who stay on drugs. So that will be a double-blinded. But really the proof of concept is part one, and that's the major question that we're trying to answer with this. And we'll be measuring lots of other parameters along the way and give updates on that. Okay, so that's PV, mycobacterium abscessus. So, again, this is a no-approved therapies by the U.S. FDA for this. So currently it's all off-label, decades-old antibiotics. There's 15,000 in the U., 50,000 if you include Japan and Europe, so major markets here. it's a rare you know disease that really causes a high five-year mortality your lungs become fibrotic you have a lot of cavities and kind of a fibrosis of the lung essentially so it's Terry it's bacteria that's related to mycobacterium tuberculosis but but quite different and and rare and so basically the the treatment for patients now that they have to contemplate is they go on multiple IV only antibiotics daily for months and years. So you can imagine this is like chemotherapy. They're taking imipenem, they're taking amikacin. These are not for the faint of heart drugs that cause hearing loss, lots of other side effects that make it very demanding for patients to do that on a daily basis, imagine. So it's like old time chemotherapy and they take oral antibiotics so that's the situation so what we're really there's not been a lot of focus on this but you know we have an oral therapeutic a petra boral so this is the same drug as SPV and the primary initial indication that we were going after this is a novel oral Lucille tRNA synthetase that's enabled by our boron chemistry so lots of companies have tried hit this target boron allows that to happen and so it's completely novel it's oral we've worked on this target for tuberculosis we licensed a compound the GSK which is in clinical trials so we know a lot about this target and about the potential of an oral therapeutic it looks incredibly good in preclinical animal models and you know we're super excited so we have a phase two program that's that's an IIT being run by Kevin Winthrop who's one of the leading KOLs in the entire space and 15 other sites across all the top KOL's in the United States so it's a multi center phase two IIT run by Kevin with with these different sites so we'll have a readout on that in late 2027 and it's a significant inflection point we believe for for our program And then we have a program in Chagas disease. This is something that many people have never heard of You get bitten by a so-called a kissing bug at night usually while you're sleeping in the face takes a blood meal and and Causes parasites much like you've probably heard of malaria or something, but there are this is the shocker 10 million people with parasites and they go into your muscle and your heart muscle and that's where the the problem is so it's this is why I got into this global health field and this is a one that affects people in all countries including the United States so there's 300,000 patients in the US but 10 million you know throughout Latin America and around the world so it shocking that we don't have a drug and it's a silent killer so about 30% of patients develop heart failure and you just drop dead one day of an aortic aneurysm or something because it's, you know, basically causes scarring in your heart muscle. So I don't think anybody wants parasites in their heart or anywhere in their body. They live there for decades for your life unless you treat it. So we have a drug. So this is, you Know, an area that really sets us apart. It's an oral 28-day therapy, and we believe it has a curative profile. We've tested it in three distinct monkey or NHP models in the state of Texas where the kissing bug resides in the U.S., infected kissing bugs. We have no idea about the transmission in the US, but it's all throughout Latin America, and these monkeys get infected in outdoor environments in the USA, and, and we treat them and we cure them so so it's about as strong of a rationale for technical success as you could possibly have going into phase two is have that monkey data who's infected by a kissing bug and it's a natural infection within monkeys and we can we can do that so we'll have top line we're starting a phase two trial in Bolivia which has the highest incidence of Chagas in the world about 8% of Bolivians have Chagos some communities it's close to a hundred percent and it'll be fast to enroll because there's millions of patients in Latin America and they're easy to find and we'll be able to have top line data next year. So quite excited about that. There won't be another company here talking about Chagas I don't think. Okay so it really is unique and then we have you know a burgeoning pipeline of earlier stage projects and you know this again we do boron chemistry we're very adept at it We've been doing it for 20 years, previously at Anacor, or we call it AN1, affectionately. And now we're AN2, which is where we get our name from. So we have a newly announced program, which is an oral EMPP1 inhibitor for hypophosphatasia. So this is a rare bone disorder. And really, it can be fatal at birth. Young infants can't form rib cages or bone. in the worst cases, and then they have various variants of genetic mutations that come up in life, and there's a bigger market in the adult space. So what I'm showing here is just some early data. We just announced a preclinical candidate, so we've selected a candidate. We made close to 1,000 analogs and really optimized for HPP in terms of potency, PK, off target activity etc so we think we have best of class profile in this these data if you're trying to read this it's it's kind of hard to read in a little bit it just this is a mouse knockout model where they're completely forced into an HPP model and we basically are showing that we're no different than well we're significantly better than than the knockout model those mice don't survive much longer than a couple of weeks their bones don't grow And we have some really interesting bone pictures. We could show you if we had more time, but it's really dramatic. So we're similar to wild-type mice. There's no difference between our drug and wild-type. And we also compare it to the gold standard here, which is Strenzic, which is an injectable therapy that treats these patients now. It's an enzyme replacement. It's quite a large market, Lexion, AstraZeneca. So these are, you know, but having an oral treatment. And so, extrinsic is injectable three to six times a week for children and adults for a lifetime. And it's really not conducive for once children get old enough to take an oral solution, an oral medication that could address this, and particularly in children, adults, you know, teenagers. So, we think it's a huge opportunity to have an oral that addresses the bone issue. Okay, ENPP1 also has interesting biology. This is where we initially started on this target, which is in oncology. So it's an immuno-oncology agent that essentially turns cold tumors that are not recognized by the immune system, the cancer hijacks that signaling pathway, into a turns-on that makes cold tumors hot, basically, where your immune system will help fight against that. So this pathway, Sting pathway and Sting agonist, have a very terrible reputation because many, you know, five years ago or so, lots of companies were going after Sting agonists. They had to inject tumors. They had terrible drug-like properties and so forth. So this gets around all of that and does it through turning on the body's innate immune system. So very excited about that program, and it's in preclinical. There recently was some interesting data. So there's a company in front of us called Rival Science that is doing the first phase two in colorectal cancer, and they have data at ESMO that's very exciting. So we, again, think the boron is perfect for this target. It binds well as a warhead, and we can build it very specific and potent compared to other chemistries that are needed to hit this target, and we think ultimately we'll have an advantage with the borone chemistry. And then lastly, we have a PI3 kinase alpha project. this is a very busy area. We view it as kind of three generations of compounds. So there's kind of first generation, which is a pellicib that hits wild type and mutants equally as potent. And the issue with that is lots of patients develop hyperglycemia and they can't tolerate it for very long. So the second generations, these are the relays of the world that really have an exciting compound. They're very kinase selective. So they separate, you know, they're much more potent against kinase than they are wild type. It's about tenfold. But they have almost no selectivity over helicase, which is about half of the mutants. And so now the third generation compounds, which would be highlighted, are equally potent against the kinase and helicases, but spares the wild type, so they're true pan-mutant selective compounds. And the highlighted compound, I would say, a synovation that Navarra has recently acquired for $2 billion. So that's the target we're going after. And boron chemistry brings uniqueness to binding in the space. It also brings uniqueness in a very crowded space to freedom to operate. So we're excited. So that just highlights some of the work. We have lots more going on before this. So lots to talk about. Just to wrap it up, there's multiple value inflection points, especially in our phase two proof of concept trials, starting with PV in early 2027 and throughout, and then both the NTM project for abscesses and Chagas disease will come in late 2027 as proof of concepts. So all those are, you know, phase two big projects. And then we have our early compounds that will be going into the clinic at the end of 2027. So hypophosphatasia and et cetera. So anyway, lots of excitement for A&2. I couldn't be more proud of this company and research team and what we've been able to do over the last few years to strengthen our pipeline and be in a position to really help patients forward and have significant value opportunity here. So thank you very much for your attention. I think we were going to do maybe a little Q&A. We've got a couple of minutes but if there's any questions otherwise we'll wrap it up yes yeah we're so obsessed as you know it's it's we're running the trial running as monotherapy you know so I think it's TBD We just had an ad board with all of our advisors, and so we're trying to look at different clinical trial designs, so we'll have more information on that. But it will be either in combination with other agents as an all-oral agent or potentially even with IV to shorten therapy duration if we can. But that's in discussions now. Yeah. Okay. All right, well, thank you very much. Thank you for watching.
- Company
- AN2 THERAPEUTICS INC
- Keywords
- AN2 THERAPEUTICS INC